Abstract
Antibody-drug conjugates (ADCs) are composed of an antibody linked to cytotoxic anticancer payloads. ADCs recognize tumor-specific cell surface antigens and are internalized into lysosomes where proteolytic enzymes release the cytotoxic payloads. Efflux transporters on plasma membrane that play a significant role on multi-drug resistance in chemotherapy can be internalized on lysosomal membrane and sequester the cytotoxic payloads. In the present study, ATP binding cassette (ABC) efflux transporters including breast cancer resistance protein (BCRP), P-glycoprotein (P-gp-MDR1), multidrug resistance protein (MRP) 2, MRP3 and MRP4 in lysosomal, and plasma membrane of tumor cells were quantified by targeted quantitative proteomics. The cytotoxicity of brentuximab vedotin and its cytotoxic payload monomethyl auristatin E (MMAE) to the tumor cell lines in the presence and absence of elacridar (P-gp-MDR1 inhibitor) or chloroquine (lysosomotropic agent) were evaluated. MMAE is a substrate for P-gp-MDR1, as the apparent efflux ratio in MDR1 transfected MDCK cell monolayers was 44.5, and elacridar abolished the MMAE efflux. Cell lines that highly express P-gp-MDR1 show higher EC50s toward the cell killing effects of MMAE. Co-incubation w...Continue Reading
References
Mar 1, 1989·Scientific American·N Kartner, V Ling
Mar 1, 1986·Cancer Letters·N ShiraishiM Kuwano
Jul 29, 2000·Cancer Treatment Reviews·M C GreenG N Hortobagyi
Sep 5, 2001·Nature Biotechnology·J M Reichert
May 24, 2005·International Journal of Pharmaceutics·Anthony M MarinoPraveen V Balimane
Jul 12, 2005·Pharmacogenetics and Genomics·Gwenaëlle ConseilSusan P C Cole
Nov 1, 2005·Journal of Pharmaceutical Sciences·Manthena V S Varma, Ramesh Panchagnula
Aug 12, 2008·Current Medicinal Chemistry·Shu-Feng ZhouYong Li
Mar 4, 2010·Cancer Research·Yelena V KovtunRavi V J Chari
Jan 12, 2011·Nuclear Medicine and Biology·Su-Jin CheongMyung-Hee Sohn
Jul 24, 2012·Science·Bin LiuXiaochen Wang
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna PrzepiorkaRichard Pazdur
May 10, 2013·Journal of Pharmaceutical Sciences·Xi QiuYurong Lai
Sep 5, 2013·Blood·Jutta DeckertJohn M Lambert
Sep 26, 2013·The Journal of Biological Chemistry·Tetsuo YamagishiDes R Richardson
Oct 22, 2013·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Radosław JanuchowskiMaciej Zabel
Dec 11, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Leonid Gibiansky, Ekaterina Gibiansky
Dec 6, 2014·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·LeeRon Shefet-Carasso, Itai Benhar
Mar 21, 2015·Journal of Medicinal Chemistry·Tong WangJeffrey P MacKeigan
Jul 17, 2015·Bioscience Reports·Christina Peters, Stuart Brown
Nov 26, 2015·The Journal of Biological Chemistry·Nicole A SeebacherDes R Richardson
Dec 4, 2015·Cancer Research·Kevin J HamblettWilliam C Fanslow
Feb 26, 2016·Molecular Pharmaceutics·Xi QiuYurong Lai
May 8, 2016·Free Radical Biology & Medicine·Nicole SeebacherPatric J Jansson
Citations
Sep 15, 2020·Technology in Cancer Research & Treatment·Ting ZhanXiaodong Huang
Jul 9, 2020·Frontiers in Immunology·Wassilis S C BruinsNiels W C J van de Donk
Jun 14, 2020·The AAPS Journal·J M Scherrmann
Oct 25, 2020·FEBS Letters·Gergely Szakacs, Rupert Abele
Jan 1, 2021·MAbs·Josefa Dela Cruz ChuhNicholas J Agard
Nov 17, 2019·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Ana Bela Sarmento-RibeiroIoannis P Trougakos
Dec 5, 2020·Molecular Cancer Therapeutics·Ryan D LyskiScott C Jeffrey
Dec 9, 2020·Molecular Cancer Therapeutics·Philip N MoquistSvetlana O Doronina
Nov 19, 2020·Journal of Clinical Pharmacology·Sheena SharmaBhagwat Prasad
Feb 9, 2021·Antibody Therapeutics·Ajeeth AdhikariChristoph Rader
Apr 9, 2021·Biological & Pharmaceutical Bulletin·Yancai LiuShan Yang
Jul 23, 2021·MAbs·Alexis Q DeanBaolin Zhang
Sep 2, 2021·Molecular Cancer Therapeutics·Samantha BuongervinoKristopher R Bosse